Who are Enlon-Plus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ecclock, Yupelri, Spiriva, Enablex, Sanctura, HEXOCYCLIUM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atropin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Enlon-Plus — Competitive Intelligence Brief

Enlon-Plus (Atropin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-Standardized Insect Allergenic Extract [EPC]. Area: Ophthalmology.

marketed Non-Standardized Insect Allergenic Extract [EPC] Muscarinic acetylcholine receptor M3 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Enlon-Plus (Atropin) — Alcon Labs Inc.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Enlon-Plus TARGET	Atropin	Alcon Labs Inc	marketed	Non-Standardized Insect Allergenic Extract [EPC]	Muscarinic acetylcholine receptor M3	1960-01-01
Ecclock	SOFPIRONIUM BROMIDE	Kaken Pharmaceutical	marketed		Muscarinic acetylcholine receptor M3	2024-01-01
Yupelri	REVEFENACIN	Mylan Ireland Ltd	marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptor M3	2018-01-01
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	marketed	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
Enablex	DARIFENACIN	AbbVie	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Sanctura	TROSPIUM	AbbVie	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
HEXOCYCLIUM	HEXOCYCLIUM	AbbVie	marketed	hexocyclium	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-Standardized Insect Allergenic Extract [EPC] class)

Alcon Labs Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enlon-Plus — Competitive Intelligence Brief. https://druglandscape.com/ci/atropin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab